文献速递类风湿关节炎

新型转录组特征可预测类风湿关节炎抗TNF-α治疗反应

Identification of a novel transcriptome signature for predicting the response to anti-TNF-α treatment in patients with rheumatoid arthritis.
PubMed 文献 · Ann Rheum Dis · 2025-09-03

本研究通过回顾性转录组分析两个公共数据集(外周血单个核细胞RNA-seq数据GSE138746和全血微阵列数据GSE33377),构建并验证了预测类风湿关节炎患者TNFi治疗反应的小规模基因特征。最终筛选出7个基因(COMTD1、MRPL24、DNTTIP1、GLS2、GTPBP2、IL18R1、KCNK17)组成的模型,在GSE33377中AUC为0.84,GSE138746内部验证AUC=0.89,外部验证AUC≥0.85,共纳入279例个体(169例应答者、110例无应答者)。

要点

  • 7基因转录组特征可预测RA患者TNFi治疗反应,外部验证AUC≥0.85。
  • GSE138746中53个差异表达基因经Benjamini-Hochberg校正后均未保持显著。
  • 18基因特征留一交叉验证预测准确率为88.75%。

核心结论

  • 识别出一个有助于预测RA患者TNFi治疗反应的转录组特征,支持其作为精准医学工具改善治疗决策并减少无效治疗暴露的潜在用途。

研究设计与样本

  • 回顾性转录组分析,使用两个公共数据集:外周血单个核细胞RNA-seq数据(GSE138746)和全血微阵列数据(GSE33377)。
  • 随后进行三次外部验证,共纳入279例个体,其中169例应答者、110例无应答者。

主要发现

  • GSE138746初始RNA-seq分析显示应答者与无应答者间有53个差异表达基因,但经Benjamini-Hochberg方法校正P值后无一保持显著。
  • 构建的18个最具区分度基因组成的小规模特征,留一交叉验证预测准确率为88.75%。
  • 进一步精简为7个基因(COMTD1、MRPL24、DNTTIP1、GLS2、GTPBP2、IL18R1、KCNK17),在GSE33377数据集中预测TNFi治疗反应的AUC为0.84。
  • GSE138746数据集内部验证AUC=0.89。
  • 外部验证确认7基因模型的稳健性(AUC≥0.85)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aims to identify and validate a transcriptomic signature capable of predicting the response to tumour necrosis factor inhibitors (TNFi) therapy in patients with rheumatoid arthritis (RA) before treatment initiation. METHODS: We performed a retrospective transcriptomic analysis using 2 public datasets, RNA-seq data from peripheral blood mononuclear cells (GSE138746) and microarray data from whole blood (GSE33377), to define a small-scale gene signature predictive of the response to TNFi treatment. Three external validations were then conducted, resulting in a total of 279 individuals, 169 responders, and 110 nonresponders. RESULTS: Initial RNA-seq analysis (GSE138746) revealed 53 genes differentially expressed between responders and nonresponders; however, none of these genes remained significant after P value adjustment with the Benjamini-Hochberg method. A small-scale genetic signature comprising the 18 most discriminatory genes was then developed, achieving a leave-one-out cross-validation predictive accuracy of 88.75%. We further refined this list to 7 genes (COMTD1, MRPL24, DNTTIP1, GLS2, GTPBP2, IL18R1, and KCNK17) that effectively predicted the response to TNFi treatment, with an area under the receiver operating characteristic curve (AUC) of 0.84 in the GSE33377 dataset. Internal validation of the GSE138746 dataset yielded an AUC = 0.89. Finally, external validation confirmed the robustness of the 7-gene model (AUC ≥ 0.85). CONCLUSIONS: We identified a transcriptomic signature that aids the prediction of the response to TNFi treatment in patients with RA. These findings support its potential use as a precision medicine tool to improve therapeutic decision-making and reduce exposure to ineffective treatments in patients with RA.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Santiago-Lamelas L, Castro-Santos P, deAndrés-Galiana EJ, et al. Identification of a novel transcriptome signature for predicting the response to anti-TNF-α treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2025. PMID: 40908203. doi:10.1016/j.ard.2025.08.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。